NYSE:EW saw its objective price increased by the researchers working at Credit Suisse Group, as they increased the price objective from $92 to $97 in one of the research notes that was sent to investors, according to reports from Benzinga. The brokerage has currently issued a rating of ‘outperform’ for this medicine company. The price target set by Credit Suisse Group is indicative of a potential upside that has occurred after the previous close of the stock- at around 16.01%.
The Research Reports on NYSE:EW
There have been several research reports issued for NYSE:EW by several analysts. Cowen has already lifted the objective price for the shares of this company from $85 to $100 and gave the company a rating of ‘outperform’ in a Monday research report. Wolfe Research has also been covering the shares of this firm, and gave them a rating of ‘underperform’ in an 11th September research report. Stifel Nicolaus also increased the price objective for the shares of this company from $85 to $90, while giving the company a rating for buy in one of the research reports that was issued on the 24th of July. Piper Sandler has also increased the price objective of the shares of NYSE:EW in a research report where the price has increased from $91 to $93. Raymond James, too, has involved themselves with this firm as they raised a price target from $88 to $90 while giving the company a rating of ‘outperform’. There have been two analysts who have given the stock a rating of ‘sell’, while five of them have issued a rating of hold, and fifteen have brought out a buy rating for this stock. NYSE:EW currently has an average rating of Buy, with a price target of $85.95.
The Quarterly Earnings of NYSE:EW
The shares of NYSE:EW opened quite strongly at around $83.61 last Thursday. The debt-to-equity ratio of the firm is 0.15, while the quick ratio is 2.24, and the current ratio is 3.08. The fifty day moving average for the firm is $82.08, and that for the 200 day is $85.06. NYSE:EW has a 1 year low of around $51.51, and a 1 year high of $87.79. The market cap for this stock is $51.98 billion, and a P/E/G ratio of 2.91, and a PE ratio is 71.87, and a beta of 0.90.
The quarterly earnings of NYSE:EW was last released on the 21st of October. The medical research company has reported an EPS of $0.51, which beat the consensus estimate set up by the analysts at around $0.45. The shares of NYSE:EW has had a net margin of around 17.31%, with a return on equity of around 29.11%.
